Elevating the Male Lupus Voice During Men’s Health Month
Elevating the Male Lupus Voice During Men’s Health Month
New Study Identifies Certain Gut Bacteria as Potential Drivers of Lupus Flares
New Study Identifies Certain Gut Bacteria as Potential Drivers of Lupus Flares
May is Lupus Awareness Month
Read about how the Lupus Foundation of America is uniting communities to raise lupus awareness and support and how you can get involved to help make lupus visible.
Toni Braxton Opens Up About Her Lupus Complications
Toni Braxton spoke recently about a “traumatic” heart procedure she underwent after she experienced a life-threatening lupus complication.
Article Credit: Lupus Foundation of America | lupus.org
New Findings in Lupus and Machine Learning
New research in machine learning finds four predictive lupus disease profiles.
Study Examines Connection Between Diet and Lupus Progression
A high-fat diet may accelerate the development of lupus, worsen lupus symptoms and increase markers of autoimmune disease in lupus-prone mice, according to new research.
Article Credit: Lupus Foundation of America | lupus.org
LUPKYNIS Continues to Show Promising Lupus Nephritis Outcomes
The drug treatment, LUPKYNIS® (voclosporin), reduced inflammation and prevented development of kidney damage in people with lupus nephritis (LN, lupus-related kidney disease) over 18 months. Those taking the medication also didn’t exhibit any signs of kidney-related toxicity. LUPKYINS® is a novel, structurally modified calcineurin inhibitor (CNI) that works in two ways – acting as an immunosuppressant through inhibition of T-cell activation and cytokine production, and by promoting podocyte stability in the kidney.
Article Credit: Lupus Foundation of America | lupus.org
Congratulations to Our Board Members
Congratulations to our board members, Dr. Sam Lim, Georgia State Rep. Kim Schofield and Founder Bryant Reid for being named Community Service awardees at the Phenomenal Women’s Health Annual Fundraising Tea.
(Pictured in the photo above l to r: Kim Schofield – Georgia State Representative, Teri Edmond – CEO of Lupus Foundation of America Georgia Chapter, Cheryl Burnside – CEO of Phenomenal Women’s Health, Bryant Reid – President of The Reid Foundation For Lupus, Inc.)
In People with Lupus, Age and Location Linked to Delayed Follow-Up After Hospitalization
March 30, 2023
Research shows younger people living with lupus and those living in rural or disadvantaged areas are less likely to have a follow-up appointment with their doctor shortly after they’ve been discharged from the hospital. One quarter of people with lupus are hospitalized every year, and one-third are re-hospitalized within 30 days, underscoring the importance of timely outpatient care.
Looking at data from 8,606 adults hospitalized with lupus on Medicare, researchers found that 35% lacked follow-up within 30 days overall. That follow-up rate is worse than the rate reported among people with other chronic diseases.
People with lupus who also exhibited the following characteristics were less likely to have a timely follow-up appointment after hospital discharge:
- More co-occurring illnesses
- A longer hospital length-of-stay
- Rural place of residency
- Greater neighborhood disadvantage
In the 65 years and older cohort, receiving timely follow-up care was associated with a 65% lower mortality rate in the month following hospital discharge, highlighting the tremendous value of outpatient treatment in this population in particular.
Regular preventative and follow-up care is critically important to living well with lupus, yet many struggle to get the medical support they need. Learn more about barriers to lupus diagnosis and care.
Article Credit: Lupus Foundation of America | lupus.org
RINVOQ Advances to Phase 3 Clinical Trials for Lupus Treatment
March 27, 2023
AbbVie announced that its drug therapy upadacitinib (also known as RINVOQ®) is entering Phase 3 clinical trial for treatment of lupus. RINVOQ is already approved for the treatment of other autoimmune conditions, such as rheumatoid arthritis, psoriatic arthritis, and eczema.
In the M19-130 Phase 2 trial of RINVOQ, the drug met its primary endpoint either given alone or as a combination therapy to people with moderately or severely active lupus disease. The drug was given to five groups, a total of 341 people, and none of the trial participants exhibited any new safety issues with the treatment.
Continue to follow the Lupus Foundation of America for updates on RINVOQ as well as other lupus clinical trials.
Article Credit: Lupus Foundation of America | lupus.org
- 1
- 2